OctoPlus N.V. Company Profile

News Articles [ 50 Associated News Articles listed on BioPortfolio]

OctoPlus N.V.: OctoPlus Announces Delisting of Shares

Leiden, the Netherlands, 15 March 2013 - OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), announces that, following the acquisition of 98.6% of all issued and outstanding ordinary sha...

OctoPlus N.V.: OctoPlus convenes EGM on 15 January 2013

With reference to the joint press releases by OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO) and Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's") dated 22 October 2012 and 16 November 2...

OctoPlus N.V.: Dr. Reddy's holds 98.6% of the shares in OctoPlus after the Post Closing Acceptance Period

This is a joint press release by Reddy Netherlands B.V. (the "Offeror"), a wholly owned subsidiary of Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's"), Dr. Reddy's and OctoPlus N.V. ("OctoPlus" or th...

OctoPlus N.V.: Dr. Reddy's Laboratories to request AFM approval for Offer Memorandum in connection with its Offer for OctoPlus N.V.

This is a joint press release by Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's") and OctoPlus N.V. ("OctoPlus" or the "Company") pursuant to Section 7, paragraph 1 sub a of the Dutch Public Takeover...

OctoPlus N.V.: Dr. Reddy's Laboratories intends to make a recommended public offer for OctoPlus N.V.

This is a joint press release by Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's") and OctoPlus N.V. ("OctoPlus" or the "Company") pursuant to the provisions of Section 5, paragraph 1, and Section 7, ...

OctoPlus N.V.: Octoplus publishes third quarter business update

Leiden, the Netherlands, 15 November 2012 - OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO) today publishes its business update for the third quarter of 2012. Dr. Reddy's intended rec...

BRIEF- OctoPlus announces delisting of shares

AMSTERDAM, March 15 (Reuters) - OctoPlus NV : * N.v. : OctoPlus announces delisting of shares

Dr. Reddy's to acquire OctoPlus

Dr. Reddy's Laboratories Ltd. (NYSE:RDY) will acquire drug delivery company OctoPlus N.V. (Euronext:OCTO) for EUR 0.52 per share in cash, or about EUR 27.4 million ($35.7 million). The price is a 30%...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [ 4 Associated Companies listed on BioPortfolio]

OctoPlus N.V.

OctoPlus is a drug product development company that is globally renowned as a center of excellence in formulation development, drug delivery and manufacturing. We offer proven and reliable service...

Dr. Reddy's Laboratories Ltd. and OctoPlus

Biolex, Inc

Biolex Therapeutics applies its unique drug development capabilities and expertise to commercialize complex proteins and monoclonal antibodies that until now have been impossible or very expensive to...

Biolex, Inc.

Biolex Therapeutics applies its unique drug development capabilities and expertise to commercialize complex proteins and monoclonal antibodies that until now have been impossible or very expensive to...